


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) ~~A compound of general formula I,~~




4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1H-imidazole or a pharmaceutically acceptable salt or hydrate thereof, ~~wherein R represents unsubstituted or substituted lower alkyl, unsubstituted or substituted aryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted lower alkylamino or a saturated five or six membered heterocyclic group containing one or two nitrogen atoms.~~

Claims 2-3. (Canceled)

4. (Currently Amended) The ~~[[A]]~~ compound according to claim ~~[[3]]~~ 1, ~~said wherein the compound being is~~ 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1H-imidazol-1-ium chloride.

Claims 5-6. (Canceled)


7. (Currently Amended) A method for the treatment of hypertension, glaucoma, migraine, diarrhea, ischemia, addiction to a chemical substance, hypotension, shock, cardiopulmonary resuscitation, a withdrawal syndrome, congestive heart failure, anxiety, or for achieving sedation or analgesia, or for reducing nasal congestion, or for achieving anesthesia with an adjunct, which comprises administering to a mammal in need thereof an effective amount of 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1*H*-imidazole or a pharmaceutically acceptable salt or hydrate thereof~~a compound of formula I,~~



~~or a pharmaceutically acceptable salt or hydrate thereof, wherein R is as defined in claim 1.~~

8. (Currently Amended) The [[A]] method according to claim 7, wherein the compound is 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1*H*-imidazol-1-ium chloride.

9. (Currently Amended) A pharmaceutical composition comprising 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1*H*-imidazole or a pharmaceutically acceptable salt or hydrate thereof ~~which comprises as an active agent a compound of formula I,~~



~~or a pharmaceutically acceptable salt or hydrate thereof, wherein R is as defined in~~
~~claim 1~~, and optionally a pharmaceutically acceptable excipient.

10. (Currently Amended) The [[A]] pharmaceutical composition according to claim 9, wherein the compound is 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1*H*-imidazol-1-ium chloride.

Claims 11-12. (Canceled)